Novavax Inc (NVAX)
$16.39
1.45 (9.71%)
NVAX Stock Quote Delayed 30 Minutes
Novavax: Bronze Medal May Be Good Enough in COVID Race
Novavax has manufacturing problems, but its vaccine candidate seems to work well against COVID-19.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.22B
PE Ratio
-5.12
EPS
-3.2
Volume (Avg. Vol.)
6.74M
Day's Range
$14.65 - $16.45
52-Week Range
$3.53 - $23.86
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
Novavax Stock Has a Lot More Going for It Than You Might Think
NVAX stock has a high valuation, while the company has had manufacturing challenges. Consequently, the risk-reward ratio is negative.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? All eyes were on Bitcoin mining stocks and bank stocks as investors closed out the week.
4 Top Stock Trades for Monday: NVAX, NVDA, PLUG, Gold
Novavax, Nvidia, Plug Power and gold were our top stock trades for Monday. Let's get a look at the stock charts after a week of record highs.
Novavax Stock Has Too Dedicated a Fanbase to Bet Against
Novavax is long on promises and it's time to deliver more concrete milestones. Meanwhile, NVAX stock remains a wild trading vehicle.
NVAX Stock: The Covid-19 Vaccine News Sending Novavax Plunging
After seeing gains early in the week, here's why investors in vaccine maker Novavax is seeing declines of more than 20% today in NVAX stock.
Despite Novavax’s Challenges, NVAX Stock Could Still Pop
NVAX stock could drop on further disappointment. But it's poised to rally big if its Covid-19 vaccine beats expectations.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? Robinhood stock posted massive gains and retail investors rallied around AMC stock.
NVAX Stock: The Huge Covid-19 News Helping Novavax Shoot Higher
NVAX stock is soaring today as the company announces its intention to supply the European Union with much-needed coronavirus vaccines.
Covid-19 Vaccine Dose Delay Spells Even More Trouble for Novavax Stock
Investors might hope that the spread of the Delta variant will boost NVAX stock, but a recent news release is likely to hinder progress.
Don’t Buy Novavax Until Its Covid-19 Vaccine Wins FDA Approval
Until Novavax secures FDA approval of its Covid-19 vaccine, investors should not buy NVAX stock, which has fallen 10% in recent days.
Novavax Stock May Not Get the Delta Varient Bump Investors Need
While NVAX stock may enjoy increased relevance on paper due to the delta variant, investors should think about the bigger picture.
Novavax Is Worth 100% More Given Its Prospects and Value Metrics
Novavax is worth roughly 100% more. NVAX stock is worth $419 given its high efficacy, cheap price, easy storage and cheap valuation compared to Moderna.
Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the Move Today
Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details.
4 Top Stock Trades for Tuesday: Bitcoin, IBM, TSCO, NVAX
Bitcoin, IBM, Tractor Supply and Novavax were our top stock trades for Tuesday. Now, let's look at the charts to see what's going on.
Plenty of Upside Potential Looms Ahead of Novavax Stock’s Bumpy Road
NVAX stock has had a turbulent 2021, but with its Covid-19 vaccine expected to go into product in Q4, growth looms.
NVAX Stock: One Big Reason Novavax Is Struggling Today
Today's significant selloff appears to be tied at least in part to some large stock sales made by the company's CEO earlier this month.
Novavax Stock Should Take Off as Its Successful Covid-19 Vaccine Spreads
Novavax should take off as its successful Covid-19 vaccine spreads. NVAX stock is worth at least 50% more, given a mixture of analysts’ estimates and comp analysis.
The Real Value of Novavax Lies in Its Pipeline, Not the Pandemic
NVAX stock is beginning to look like all the good news is priced in. However, a successful Covid-19 vaccine may be a catalyst for other vaccines.
NVAX Stock Is Not For The Faint Of Heart
On June 14, Novavax announced that its Covid-19 vaccine, officially called "NVX-CoV2373," proved to be 93% effective against the Coronavirus and its variants in a phase 3 clinical trial. The vaccine was 100% effective against severe versions of Covid-19. The Gaithersburg, Maryland-based company now says it will file for "Emergency Use Authorization" of its vaccine with the U.S. Food and Drug Administration (FDA).
